IPSEN PHARMA | MedPath

Ipsen Secures €500 Million Inaugural Rated Public Bond Following Investment Grade Ratings

2 months ago

• Ipsen has successfully completed its first Rated Public Bond of €500 million with a 3.875% coupon maturing in March 2032, following Investment Grade ratings from S&P (BBB-) and Moody's (Baa3). • The transaction was heavily oversubscribed by institutional investors, demonstrating market confidence in Ipsen's financial strategy and long-term growth prospects. • This bond issuance is part of Ipsen's broader refinancing plan, which recently included the renewal of a €1.5 billion Revolving Credit Facility, significantly extending the company's debt maturity profile.

NALIRIFOX Shows Numerically Improved Overall Survival Compared to FOLFIRINOX in Metastatic PDAC

4 months ago

• A real-world study indicated that first-line NALIRIFOX had a numerically higher median overall survival (OS) of 11.1 months compared to FOLFIRINOX's 9.1 months in mPDAC patients. • The analysis included a trial-aligned cohort, an all-comer cohort, and a modified FOLFIRINOX cohort, assessing survival outcomes in metastatic pancreatic ductal adenocarcinoma. • The findings suggest NALIRIFOX may offer a survival advantage over FOLFIRINOX in treating mPDAC, warranting further studies adjusting for baseline characteristics. • Data were sourced from the Flatiron Electronic Health Record, covering patients treated between January 2014 and February 2024, providing a comprehensive real-world view.

PBC Treatment Landscape Evolves with New Drug Approvals and Regulatory Scrutiny

7 months ago

• The FDA approved Iqirvo (elafibranor, Ipsen/Genfit) as a second-line treatment for primary biliary cholangitis (PBC) in patients with inadequate response or intolerance to UDCA. • Livdelzi (seladelpar, Gilead) also received accelerated FDA approval for PBC, offering another option for patients who do not respond to or cannot tolerate UDCA. • An FDA advisory committee voted against the full approval of Ocaliva (obeticholic acid), raising concerns about its long-term safety and efficacy data. • These developments mark a significant shift in the PBC treatment paradigm, introducing new therapeutic options and challenging the existing market landscape.